SynthesisBMJ mental health2025
Longitudinal associations of electroconvulsive therapy with all-cause mortality and suicide deaths in severe unipolar or bipolar depression: a systematic review and meta-analysis.
Synthesis in BMJ mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electroconvulsive therapy: improved understanding of long-term risks and benefits from advances in administrative health data.The British journal of psychiatry : the journal of mental science · 2026Review
- Review
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundElectroconvulsive therapy (ECT) is among the most effective treatments for treatment-resistant mood disorders.
objectiveThis study aims to meta-analyse the effects of ECT on all-cause mortality and suicide deaths in severe unipolar or bipolar depression using longitudinal studies. STUDY SELECTION AND ANALYSIS: PubMed/MEDLINE, PsycINFO, Cochrane Library, Embase and Google Scholar were searched from inception through 21 January 2025. Inclusion criteria were: (1) patients with diagnoses of mental disorders; (2) intervention consisted of ECT compared with placebo, usual care or another intervention; (3) all-cause mortality and suicide deaths as outcomes measures; and (4) clinical trial or longitudinal cohort study designs where the aforementioned interventions preceded the observations of outcome measures. Adjusted HR with their corresponding 95% CIs were estimated using random-effects models. Moderator analyses were also performed.
findingsOverall, 17 studies consisting of 1 182 501 individuals (n=40 867 for patients with ECT, n=1 141 634 for patients with non-ECT) were included. 94.1% of the studies focused on patients with unipolar or bipolar depression and one study was focused on schizoaffective disorder. ECT was associated with a reduction in risk of all-cause mortality (HR 0.70 (95% CI 0.61 to 0.81); p<0.001), a finding that was consistent at 3 months, 6 months and 12 months of follow-up. Regions had a moderating effect; Japan had the largest effect size (HR 0.17 (95% CI 0.04 to 0.72)) and Denmark had the smallest (HR 0.87 (95% CI 0.83 to 0.92)). ECT was associated with a reduction in suicide risk at 3 months of follow-up (HR 0.53 (95% CI 0.39 to 0.72); p<0.001) but not at 1, 6 or 12 months of follow-up.
conclusionsECT is associated with a reduced risk of all-cause mortality. However, ECT use for suicide protection appears transient and inconsistent. CLINICAL IMPLICATIONS: ECT may be safely used among patients with severe unipolar or bipolar depression. PROSPERO REGISTRATION NUMBER: CRD42025641749.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.